Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:44:28 EDT Sat 12 Jul 2025
Enter Symbol
or Name
USA
CA



News for U:LXRX from 2024-07-12 to 2025-07-11 - 45 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-06-23 08:00U:LXRXNews ReleaseData Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
2025-06-18 08:30U:LXRXNews ReleaseLexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
2025-05-29 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
2025-05-19 08:00U:LXRXNews ReleaseSONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
2025-05-13 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
2025-05-06 16:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
2025-05-06 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
2025-04-02 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
2025-03-28 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
2025-03-07 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
2025-03-06 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
2025-03-04 16:15U:LXRXNews ReleaseLexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
2025-03-03 07:00U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
2025-03-02 16:13U:LXRXNews ReleaseLexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
2025-02-18 08:00U:LXRXNews ReleasePublished Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
2025-01-21 08:00U:LXRXNews ReleaseLexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
2025-01-02 08:00U:LXRXNews ReleaseLexicon Appoints Scott Coiante as Chief Financial Officer
2024-12-20 16:31U:LXRXNews ReleaseLexicon Announces Receipt of Complete Response Letter for Zynquista(TM) (sotagliflozin)
2024-11-26 08:00U:LXRXNews ReleaseLexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
2024-11-25 16:15U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in December Investor Conferences
2024-11-22 07:32U:LXRXNews ReleaseLexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
2024-11-20 16:06U:LXRXNews ReleaseLexicon Appoints Ivan H. Cheung to Board of Directors
2024-11-14 08:00U:LXRXNews ReleasePost-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago
2024-11-12 16:05U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-11-06 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
2024-11-05 16:05U:LXRXNews ReleasePublished Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
2024-11-05 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
2024-11-04 08:00U:LXRXNews ReleaseLexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
2024-10-31 18:55U:LXRXNews ReleaseLexicon Announces Outcome of FDA Advisory Committee for Zynquista(TM) (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
2024-10-23 09:00U:LXRXNews ReleaseNew Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
2024-10-22 08:00U:LXRXNews ReleaseLexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
2024-10-16 16:35U:LXRXNews ReleaseLexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
2024-10-16 16:34U:LXRXNews ReleaseViatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
2024-09-27 08:00U:LXRXNews ReleaseLexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
2024-09-16 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
2024-09-10 08:00U:LXRXNews ReleaseNew Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
2024-09-03 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
2024-09-03 08:00U:LXRXNews ReleaseNew Secondary Analysis of Phase 3 Data Demonstrates that INPEFA(TM) (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
2024-08-21 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
2024-08-13 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
2024-08-07 08:00U:LXRXNews ReleaseEfficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
2024-08-01 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-07-25 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
2024-07-16 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
2024-07-15 08:00U:LXRXNews ReleaseNew Published Data Highlights Potential Cost-Savings of INPEFA(TM) (sotagliflozin) for Heart Failure